London, UK; Brentwood, TN; 4 December 2006 - Protherics PLC ("Protherics" or the
"Company"), the international biopharmaceutical company focused on critical care
and cancer, announces that, on 1 December 2006, it received notification from
Barclays PLC that, as at 27 November 2006, Barclays PLC held an interest in
9,730,366 ordinary shares, representing 3.72% of the issued share capital of the
Company.
